Fenwick & West represented CoreWeave, Inc. in the offering, and Latham & Watkins represented the underwriters. CoreWeave, Inc. (Nasdaq: CRWV), a developer of a cloud infrastructure...
CoreWeave’s $2 Billion Upsized IPO
SMART Global Holdings’ $175 Million Convertible Notes
Latham & Watkins advised SMART Global Holdings Inc. SMART Global Holdings, Inc. closed a US$175 million in aggregate principal amount of convertible senior notes due 2030,...
Illumina’s Divestiture of GRAIL
Cravath, Swaine & Moore represented Illumina, Inc. on the transaction, and Latham & Watkins represented GRAIL, LLC. GRAIL, Inc. (NASDAQ: GRAL, formerly GRAIL, LLC), a healthcare...
Neumora Therapeutics’ $250.1 Million Initial Public Offering
Latham & Watkins advised Neumora, and Cooley advised the underwriters. Neumora Therapeutics, Inc. announced the pricing of its initial public offering of 14,710,000 shares of its common...
LegalZoom’s $140 Million Secondary Offering of Common Stock
Cooley advised LegalZoom, Latham advised the underwriters, and Fried Frank advised the selling stockholder on the offering. LegalZoom.com, Inc. (Nasdaq: LZ) priced the previously announced underwritten...
CytomX’s Research Collaboration With Moderna
Latham & Watkins LLP advised CytomX in the transaction. CytomX Therapeutics, Inc. (NASDAQ: CTMX), a leader in the field of conditionally activated oncology therapeutics and Moderna,...
Geron Corporation’s $198 Million Upsized Public Offering
Cooley advised Geron, while Latham & Watkins represented the underwriters in the offering. Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, has announced the pricing...
IDEAYA Biosciences’ $80 Million Common Stock Offering
Latham & Watkins represented IDEAYA, while Davis Polk advised the representatives of the several underwriters in the offering. IDEAYA Biosciences, Inc. (Nasdaq: IDYA) announced the pricing of an...
Ardelyx’s $20 Million Agreement with HealthCare Royalty Partners
Latham & Watkins represented Ardelyx, Inc. in the transaction in the transaction. Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop...
AMD’s $1 Billion Senior Notes Offering
Latham & Watkins represented AMD, while Davis Polk advised the representatives of the several underwriters in the offering. AMD (NASDAQ: AMD) has priced an underwritten public offering...
Absci Corporation’s $200 Million Initial Public Offering
Goodwin Procter advised Absci, while Latham & Watkins represented the underwriters in the offering. Absci Corporation (Absci), the synthetic biology company unlocking the potential of proteins...
Aligos Therapeutics’ $83.6 Million Public Offering
Latham & Watkins LLP represented Aligos Therapeutics, while Davis Polk advised the representatives of the several underwriters in the offering. Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced...